Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (17524)	1/6/1999 6:41:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 23519

Vlad,,,,do you see the conflicts that this causes with Astra and Janssen???? If LLY is allowed to market Muse/Alibra in the USA with the lead in to market ICOS oral Ed solution 2 years down the road. Astar and Janssen have both signed exclusive agreements with VVUS ...they can not sell other ED solutions. Astra and Janssen are only licenced to sell MUSE. LLY may want to sell Alibra in the same markets that Astra and Janssen are now selling MUSE. It opens up a very interesting and complex sales deal for all parties. Not an easy yes/no pick partner A or B.......... That's why they need the expertise of CS First Boston to help work out the details. All of this takes time......